Enocitabine
Based on 1 Customer Validation
Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.32%
- No. CAS: 55726-47-1
- Fòrmula: C31H55N3O6
- Peso molecular:565.78
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
Enocitabine is resistant to deamination because Enocitabine bears a highly lipophilic group at the 4-amino position of the cytosine moiety of cytarabine[1].
The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells[2].
In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 55726-47-1
-
Appearance Solid
-
Peso molecular 565.78
-
Fòrmula C31H55N3O6
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCCCCCCCCC(NC(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@H](O2)CO)=NC1=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
H2O : < 0.1 mg/mL (insoluble)
Pureza y Documentación
-
Ficha de datos (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Hamada A, et al. Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet. 2002;41(10):705-18. [Content Brief]
[2]. Nagasawa M, et al.In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines. Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 1):633-8. [Content Brief]
[3]. Nakamura K, et al. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990 Jun;31(2):141-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)